CytoDyn (CYDY) Non-Current Deferred Tax Liability (2012 - 2013)
CytoDyn (CYDY) posted Non-Current Deferred Tax Liability of $155500.0 for Q2 2013, up 61.14% on a QoQ basis from $96500.0 in Q2 2012, and up 61.14% year-over-year from $96500.0 in Q2 2012.
CytoDyn (CYDY) Non-Current Deferred Tax Liability (2012 - 2013) Analysis & Trends
CytoDyn's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $155500.0 for Q2 2013.
- Quarterly Non-Current Deferred Tax Liability rose 61.14% year-over-year to $155500.0 in Q2 2013, while the trailing twelve-month figure through May 2013 was $155500.0 (up 61.14% YoY) and the FY2013 annual result came in at $155500.0, up 61.14% from the prior year.
- Non-Current Deferred Tax Liability was $155500.0 for Q2 2013 at CytoDyn, up from $96500.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $155500.0 in Q2 2013 and bottomed at $96500.0 in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | CytoDyn | 267.79 Mn | 267.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2013 | 155,500.00 |
| May 31, 2013 | 155,500.00 |
| May 31, 2012 | 96,500.00 |
| May 31, 2012 | 96,500.00 |